Zimmer Biomet Holdings, Inc. (ZBH - Free Report) announced the global launch of the Persona Partial Knee System on Aug 31. This is an advanced addition to the company’s portfolio of personalized and anatomically designed knee implant systems. Since the acquisition of Biomet, Persona Partial Knee System is the first developed product of the consolidated company.
The Persona Partial Knee System provides surgeons with a comprehensive system of implants and instruments to offer excellent fit and accuracy in the operating room. As per Zimmer Biomet, this fixed-bearing system complements the mobile-bearing Oxford Partial Knee of the company.
Following the launch, the first surgery with Persona Partial Knee System was a success.
In the last reported second quarter, revenues from the Knees segment were down 1.3% year over year at CER and the company has been observed to put consistent efforts to boost this business. Taking into consideration the growing global knee implant market, we believe the latest development will boost the company's sales in this niche.
In this regard, we note that according to a BCC Research report, the global market for joint reconstruction and replacement is expected to increase to nearly $16.2 billion by 2018, at a CAGR of 4.2% from 2013 through 2018. The U.S. market is expected to reach a worth of $10.3 billion by 2018 at a CAGR of 5.1%. The European and Japanese markets are estimated to reach a worth of $4.5 billion and $1.3 billion by 2018, at a respective CAGR of 3.3% and 1.4%.
Another major development in Zimmer Biomet’s Knees business is thelaunch of an X-ray-based Patient Specific Instrument — X-PSI Knee System. This is the world's first CE Marked surgical planning system which enables patient-specific implant positioning, solely using X-ray technology.
Over the past month, Zimmer Biomet has been trading above the broader industry. The company has gained 2.9%, when compared to the 2.1% gain of the broader industry.
Zacks Rank & Key Picks
Zimmer Biomet carries a Zacks Rank #4 (Sell). A few better-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Chemed Corporation (CHE - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and Chemed carry a Zacks Rank #2 (Buy). You cansee the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 23% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 19.2% over the last six months.
Chemed has a long-term expected earnings growth rate of 10%. The stock has gained around 4.1% over the last six months.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>